Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection [2]

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 7, 2006, Pages 824-825

  Yu, Wai Cho ^a   Lai, Sik To ^a   Chiu, Ming Chee ^a   Chau, Tai Nin ^a   Ng, Tak Keung ^a   Tam, Cheuk Ming ^b  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; LAMIVUDINE; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AFRICA; DISEASE ASSOCIATION; DRUG TOLERANCE; FEVER; HEPATITIS B; HUMAN; INFECTIOUS HEPATITIS; LABORATORY TEST; LETTER; LIVER DYSFUNCTION; LUNG TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B; HUMANS; ISONIAZID; LAMIVUDINE; MALE; MIDDLE AGED; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 33745830473     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Combs D L, O'Brien R J, Geiter L J. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112: 397-406.
2. Pande J N, Singh S P, Khilnani G C, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
3. Lee W M. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
4. Lai C L, Chien R N, Leung N W, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
5. Dienstag J L, Schiff E R, Wright T L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.